Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 5/20 | 0.38 |
| ▸ | TNF | P01375 | 1/20 | 0.37 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PRKCD | Q05655 | 4/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10159093 | 1.00 | NPSR1 (0.41) | NPSR1GAARIPK1TNFTAS2R8 | |
| SCHEMBL12049657 | 1.00 | NPSR1 (0.41) | NPSR1GAARIPK1TNFTAS2R8 | |
| SCHEMBL12408237 | 0.80 | NPSR1 (0.43) | NPSR1GAARIPK1TNFKMT2A | |
| SCHEMBL14687910 | 0.79 | ALDH1A1 (0.41) | NPSR1GAARIPK1TNFKMT2A | |
| SCHEMBL16001119 | 0.79 | RIPK1 (0.42) | NPSR1GAARIPK1TNFKMT2A | |
| SCHEMBL15026061 | 0.79 | ALDH1A1 (0.41) | NPSR1GAARIPK1TNFKMT2A | |
| SCHEMBL22702838 | 0.79 | ALDH1A1 (0.41) | NPSR1GAARIPK1TNFKMT2A | |
| SCHEMBL1362696 | 0.79 | RIPK1 (0.42) | NPSR1GAARIPK1TNFKMT2A | |
| SCHEMBL25404225 | 0.77 | RIPK1 (0.38) | NPSR1GAARIPK1TNFKMT2A | |
| SCHEMBL13799221 | 0.77 | RIPK1 (0.38) | NPSR1GAARIPK1TNFKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193164-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-8193164-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-20100190784-A1 | Organic Compounds | NOVARTIS AG | 2010-07-29 | — | — | US | disclosed |
| US-20100190784-A1 | Organic Compounds | NOVARTIS AG | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190784-A1 | Organic Compounds | CYP1B1, POLR2A, CYP1A1 | NPSR1 2203/4885GAA 1362/4885RIPK1 4351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.